Medivir Ab · OMXSTO:MVIR
Medivir Ab — Q2 2025 Earnings Presentation
20 slides from Medivir Ab's earnings presentation, Aug 21, 2025
Slide 1: Medivir Q2 Report 2025
Placeholder agenda Medivir Improving Q2 REPORT life for 2025 advanced liver cancer (HCC) patients Fostrox – Displacing The first oral, chemotherapy liver-targeted with the treatment first oral, liver-activated forofadvanced inhibitor HCC DNA replication
Slide 2: Important notice
Important notice You must read the following before continuing. The following applies to this document and the information provided in this presentation by Medivir AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection wit
Slide 3: Q2 Highlights
Q2 Highlights Placeholder agenda ASCO & ESMO-GI data presentations confirm fostrox frontrunner position in 2L HCC Japan patent for fostrox + lenvatinib approved, providing protection until 2041, complementing previous approvals in EU and Australia Concentra acquiring IGM Biosciences, birinapant retu
Slide 4: Today's presenters
Today’s presenters CEO CMO CFO CSO Jens Lindberg Pia Baumann Magnus Christensen Fredrik Öberg Slide 4
Slide 5: ASCO & ESMO-GI data presentations confirm fostrox frontrunner position in 2L HCC
ASCO & ESMO-GI data presentations confirm fostrox frontrunner position in 2L HCC Slide 5
Slide 6: ASCO and ESMO-GI presentations confirm gap in clinical data in 2nd line advanced HCC
ASCO and ESMO-GI presentations confirm gap in clinical data and lack of consensus in 2nd line advanced HCC 1st line 2nd & 3rd line Slide 6
Slide 7: Median PFS: 2.96 months (95% CI, 2.27 – 9.17)
Median PFS: 2.96 months (95% CI, 2.27 – 9.17) • 22 patients with progression on prior treatment enrolled at 7 sites in Germany • Treated with cabozantinib 60 mg once daily Slide 7
Slide 8: HCC patients on 2L treatment post atezolizumab + bevacizumab
• 230 HCC patients on 2L treatment post atezolizumab + bevacizumab; lenvatinib (n=125) or sorafenib (n=105) • Study confirmed lenvatinib superiority over sorafenib and similar efficacy for lenvatinib monotherapy as in previous studies: • Median PFS of 5.5 months • Disease Control Rate of 57.7% Slide
Slide 9: Recent review of HCC studies in 2nd line confirms unmet need
Recent review of HCC studies in 2nd line confirms unmet need with an ORR < 10% and a PFS of around 4 months Chan et al., “Treatment for hepatocellular carcinoma after immunotherapy” Annals of Hepatology, February 2025 TKIs (lenvatinib, sorafenib etc) Fostrox + lenvatinib Mean results across 8 studie
Slide 10: Treatment outcome substantially improved with Fostrox + Lenvima
Treatment outcome substantially improved with Fostrox + Lenvima compared to Lenvima monotherapy and other 2L HCC treatments Median TTP (Kaplan-Meier) with fostrox + Lenvima Median TTP/PFS vs previous studies in 2L HCC ~3.5-4 months Lenvima after IO combo: Fostrox + LEN (n =21)1 Kobayashi et al. 2023
Slide 11: Objective, results, conclusions and relevance
OBJECTIVE RESULTS CONCLUSIONS AND RELEVANCE • To compare the HR-QoL effects • Atezolizumab plus bevacizumab had • Atezolizumab plus bevacizumab associated with different first-line the highest probability of reducing provides the best balance between treatments for unresectable or deterioration of g
Slide 12: Recent data cements current treatment algorithm, strengthening potential for Fostrox
Recent data cements current treatment algorithm in, further strengthening the potential for Fostrox to be first in 2L HCC Advanced HCC – Treatment Algorithm 1L 90% 10% • Majority treated with IO combo • Tecentriq + Avastin preferred with recent data strengthening its position IO combination Lenvatin
Slide 13: 2nd line HCC – a large and growing commercial opportunity
2nd line HCC – a large and growing commercial opportunity with significant need for new treatment options3 $4.0 bn Growth driven by: HCC to increase +122% in the US and +82% in China2 by 2030, caused by fatty liver disease +115% $2.8 bn With improved 1L treatment, more patients will be fit enoug
Slide 14: Growth in Fatty Liver Disease expected to drive increase in liver cancer cases
Growth in Fatty Liver Disease expected to drive an alarming increase in liver cancer cases1 Fatty Liver Disease (MASLD/MASH) expected to rise dramatically over the next 30 years The number of newly diagnosed liver cancer patients each year is expected to double HCC market growth further spurred by m
Slide 15: Key patent approval in Japan for fostrox + Lenvima extending protection until 2041
Key patent approval in Japan for fostrox + Lenvima extending protection until 2041, complementing previous approval in EU Covers the combination of fostrox + Lenvima for the treatment of HCC and metastases to the liver Now approved in Japan, EU and Australia which indicates likelihood of other key r
Slide 16: Financial highlights Q2
Financial highlights Q2 Slide 16
Slide 17: Financial summary Q2, 2025
Financial summary Q2, 2025 Consolidated Income Statement, summary Q2 Q1 - Q2 Full year (SEK m) 2025 2024 2025 2024 2024 Net turnover 1.5 1.1 2.1 1.6 3.5 Other operating income 0.3 0.1 0.5 0.3 1.0 Total income 1.8 1.2 2.6 1.9 4.5 Other external expenses -17.0 -30.3 -23.2 -51.0 -101.3 Personnel costs
Slide 18: Q/A
Q/A Slide 18
Slide 19: Fostrox (fostroxacitabine bralpamide)
Fostrox (fostroxacitabine bralpamide) The first oral, liver-targeted treatment tailored for HCC Oral, liver-activated small molecule inducing DNA 10.9 months time to progression, damage in tumor cells, sparing healthy liver cells3 substantially better than SoC1,2 12 Unique, liver-targeted No DNA dam
Slide 20: Thank You!
Thank You! Slide 20